Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 02 symbols : NVS save search
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Published: 2021-06-02 (Crawled : 14:00) - biospace.com/
NVS | $93.07 -1.42% 280K
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
media cancer breast cancer her2+ her2- her2 metastatic breast cancer
Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
Published: 2021-06-02 (Crawled : 13:15) - globenewswire.com
NVS | $93.07 -1.42% 280K
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
trial response
APAC Gene Therapy Market Size To Be $6,931.5 Million by 2030 says P&S Intelligence
Published: 2021-06-02 (Crawled : 09:00) - prnewswire.com
NVS | $93.07 -1.42% 280K
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
AMGN | $265.07 -0.17% 280K
|
Health Technology
|
| O: 0.57%
H: 0.76%
C: 0.11%
gene therapy therapy gene therapies
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
Published: 2021-06-02 (Crawled : 06:00) - globenewswire.com
NVS | $93.07 -1.42% 280K
|
Health Technology
|
| O: 0.85%
H: 0.37%
C: 0.02%
treatment potential positive results
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
WISA 4 | $3.17 81.14% 36M
|
Electronic Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 38M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.